Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose

Inclusion Criteria: * Free written informed consent prior to any procedure required by the study. * Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study. * Willingness to accept and comply with all study procedures and restrictions. * Male or female subject between 18 and 75 years, inclusive, at Screening. * Body mass index (BMI) of 18.0 to 35.0 kg/m\^2, inclusive, at Screening. * A female subject is eligible if she meets one of the following criteria: 1. is of non-childbearing potential (underwent a permanent sterilization method \[e.g., hysterectomy, bilateral salpingectomy and bilateral oophorectomy\], is clinically diagnosed infertile, or is in a post-menopausal state); or 2. is of childbearing potential and agrees to use an accepted contraceptive method from at least 28 days prior to dose administration (prior to first dose administration for Group 5) until at least 1 month after the end of study (EOS). * Negative test results for anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (anti-HCVAb). * Stable concomitant medications for at least 7 days prior to dose administration (first dose administration for Group 5) and up to the EOS. Additional Inclusion Criteria for Subjects with Renal Impairment (Groups 2 to 5) * eGFR at Screening, determined by the Cockcroft-Gault equation, within: * 60-89 mL/min for Group 2 (mild renal impairment subjects). * 30-59 mL/min for Group 3 (moderate renal impairment subjects). * 15-29 mL/min for Group 4 (severe renal impairment subjects). * \<15 mL/min for Group 5 (ESRD subjects) * Subjects with ESRD are on dialysis for at least 3 months prior to Screening. * Systolic blood pressure (SBP) 100-180mmHg, diastolic blood pressure (DBP) 50-105 mmHg, and pulse rate 50-100 bpm (inclusive), at Screening and Admission. Additional Inclusion Criteria for Subjects with Normal Renal Function (Group 1) * Estimated glomerular filtration rate (eGFR) ≥90 mL/min at Screening, determined by the Cockcroft-Gault equation. * No clinically relevant abnormalities on clinical laboratory tests at Screening. * Blood pressure and pulse rate at Screening within the following ranges: * SBP 90-140 mmHg, DBP 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \<65 years of age. * SBP 95-160mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥65 years of age. Exclusion Criteria: * Known hypersensitivity/allergy reaction to cytisinicline substance or any of the excipients. * History of renal, heart, and/or liver transplant. * History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment except for renal disease. * Symptoms of an acute clinically relevant infection in the 4-week period preceding Screening (e.g., bacterial, viral, or fungal infection). * History or clinical evidence of alcohol use disorder or substance use disorder according to Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) classification, within the 3-year period prior to Screening. * Clinically relevant abnormalities on a 12-lead electrocardiogram (ECG), recorded after 5 min in the supine position at Screening. * Currently using any creatine supplement. * Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 hours prior to Admission. * Excessive caffeine consumption, defined as ≥800 mg per day at Screening. * Positive result in drugs-of-abuse or ethanol tests at Screening or Admission. NOTE: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive. * Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture). * Participation in any clinical trial within the previous 2 months. * Loss of 250 mL or more blood within 3 months prior to screening. * If female, positive pregnancy test in serum at Screening or positive pregnancy test in urine at Admission. * If female, she is breast-feeding. Additional Exclusion Criteria for subjects with Renal Impairment (Group 2 to 5) * Presence of severe cardiac disease. * History of severe renal artery stenosis. * Presence of unstable diabetes mellitus. * Acute, ongoing, recurrent, or chronic systemic disease other than renal function impairment that could interfere with the evaluation of the study results. * Presence of any organ disorder, except for renal function impairment, which might interfere with the PK of cytisinicline. * Use of any medication which might interfere with the PK of cytisinicline. * Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis), except for those related to renal impairment, at Screening. Additional Exclusion Criteria for Subjects with ESRD (Group 5) * Blood hemoglobin \<10 g/dL at Screening.